OneMedNet Corporation announced the next phase of its commercial launch of a Real‑World Data (RWD) platform that is powered by Palantir’s Foundry data‑integration platform. The new offering delivers regulatory‑grade, AI‑ready data to healthcare customers, leveraging Foundry’s ontology‑based data modeling to enable secure, auditable analytics across patient populations.
The platform aggregates data from more than 2,130 healthcare sites, providing over 20 years of historical depth and three years of forward coverage. Its AI‑driven search and multimodal data access allow users to query structured and unstructured data in a conversational interface, while Foundry’s governance framework ensures compliance with privacy and regulatory requirements. The integration positions OneMedNet as a scalable, prospective data feed provider for real‑world evidence generation.
Palantir’s partnership with OneMedNet expands the company’s footprint in the regulated healthcare sector, where data security and governance are paramount. By embedding Foundry into its RWD offering, Palantir opens a new revenue stream and reinforces its strategy of embedding its platform into industry‑specific ecosystems. The deal aligns with the rapid adoption of AI for clinical decision support and regulatory reporting, and it strengthens Palantir’s competitive moat in the growing AI‑enabled healthcare analytics market.
Palantir’s Q4 2025 results underscore the strategic value of this partnership. Revenue rose 70% year‑over‑year to $1.407 billion, and adjusted earnings per share beat expectations by $0.24, driven by strong demand in the U.S. commercial segment, which grew 137% to $507 million. The company guided fiscal 2026 revenue to $7.18‑$7.20 billion, a 61% increase over the prior year, and maintained a 57% adjusted operating margin. CEO Alex Karp described the results as “truly iconic performances in the history of corporate performance or technology,” while CFO David Glazer highlighted the company’s highest ever revenue growth rate and the ability to scale AI platform monetization.
OneMedNet’s financial health remains a concern, with a 56.1% decline in revenue growth over the past three years and negative profitability margins. Nevertheless, the partnership is expected to generate millions in incremental annual recurring revenue. CEO Aaron Green said, “OneMedNet’s platform is redefining how organizations access and operationalize real‑world data through the continued expansion of our products and solutions. Customer feedback has reinforced the platform’s performance, speed, and depth of discovery. We believe this traction validates our strategy of combining conversational AI‑driven search with scalable, prospective data feeds, strengthening customer confidence as we expand subscriptions and deliver fast, intuitive value for Real‑World evidence generation.”
Analysts have responded positively to Palantir’s strong Q4 performance and forward guidance. Mizuho upgraded the company to “Outperform” with a $195 price target, Citigroup issued a “Buy” rating, and UBS set a $180 target. The consensus price target from 27 analysts is $162.96. The market reaction reflects confidence in Palantir’s high‑growth trajectory and the strategic importance of its healthcare expansion, while also noting the company’s high valuation multiples.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.